Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | WDR5 | P61964 | 14/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5306345 | 0.88 | LMNA (0.41) | LMNAALDH1A1WDR5NPC1RAB9A | |
| SCHEMBL5375885 | 0.85 | LMNA (0.42) | LMNAALDH1A1WDR5NPC1RAB9A | |
| SCHEMBL20337613 | 0.82 | WDR5 (0.44) | LMNAALDH1A1WDR5 | |
| SCHEMBL5329805 | 0.80 | WDR5 (0.39) | LMNAALDH1A1WDR5 | |
| SCHEMBL5303254 | 0.80 | MAPK14 (0.38) | LMNAALDH1A1WDR5KDM4E | |
| SCHEMBL5311345 | 0.80 | WDR5 (0.41) | LMNAALDH1A1WDR5NPC1RAB9A | |
| SCHEMBL18281441 | 0.78 | WDR5 (0.38) | LMNAALDH1A1WDR5SMN1; SMN2MAPT | |
| SCHEMBL5306661 | 0.78 | WDR5 (0.40) | LMNAALDH1A1WDR5KDM4E | |
| SCHEMBL18281430 | 0.78 | MAPK14 (0.46) | LMNAALDH1A1WDR5NPC1RAB9A | |
| SCHEMBL5305026 | 0.77 | LMNA (0.47) | LMNAWDR5KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007034282-A2 | DIARYL-IMIDAZOLE COMPOUNDS CONDENSED WITH A HETEROCYCLE AS C3A RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | claimed |
| US-10933049-B2 | Mobilizing agents and uses therefor | THE UNIVERSITY OF QUEENSLAND (AU) | 2021-03-02 | — | — | US | disclosed |
| US-20180185328-A1 | MOBILIZING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2018-07-05 | — | — | US | disclosed |
| EP-3302710-A1 | MOBILIZING AGENTS AND USES THEREFOR | The University of Queensland (AU) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016191811-A1 | MOBILIZING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-12-08 | — | — | WO | disclosed |
| WO-2007034282-A2 | DIARYL-IMIDAZOLE COMPOUNDS CONDENSED WITH A HETEROCYCLE AS C3A RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185328-A1 | MOBILIZING AGENTS AND USES THEREFOR | C3AR1, CSF3R, C5AR1 | LMNA 3889/4885ALDH1A1 2492/4885WDR5 2932/4885 |
| US-10933049-B2 | Mobilizing agents and uses therefor | C3AR1, CSF3R, C5AR1 | LMNA 3889/4885ALDH1A1 2492/4885WDR5 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.